Related Experiment Video
Updated: Apr 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nucleoside-sparing antiretroviral regimens
Pola de la Torre1, Jomy George, John D Baxter
1Cooper University Hospital, Cooper Medical School of Rowan University, Camden, NJ, USA, delaTorre-pola@cooperhealth.edu.
Abstract:
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first drugs approved for use as antiretroviral therapy in patients infected with HIV. Despite the introduction of other classes of antiretroviral drugs, they remain an important component of combination regimens as recommended by many treatment guidelines. They also continue to be used in prevention of disease from mother to child, postexposure prophylaxis, and more recently for preexposure prophylaxis. Unfortunately, the toxicities associated with this class of drugs can limit their use. Although NRTI-sparing regimens are not currently recommended for first-line therapy there is an increasing amount of data supporting their use in both treatment-naive and in treatment-experienced patients.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retroviruses
Retrovirus Life Cycles
Subviral Agents
Viruses with RNA Genomes
Pharmacokinetics in Pediatric Patients: Drug Excretion

